PT - JOURNAL ARTICLE AU - Chang-Monteagudo, Arturo AU - Ochoa-Azze, Rolando AU - Climent-Ruiz, Yanet AU - Macías-Abraham, Consuelo AU - Rodríguez-Noda, Laura AU - Valenzuela-Silva, Carmen AU - Sánchez-Ramírez, Belinda AU - Perez-Nicado, Rocmira AU - González-Mugica, Raúl AU - Hernández-García, Tays AU - Orosa-Vázquez, Ivette AU - Díaz-Hernández, Marianniz AU - de los A. García-García, María AU - Jerez-Barceló, Yanet AU - Triana-Marrero, Yenisey AU - Ruiz-Villegas, Laura AU - Rodríguez-Prieto, Luis AU - Puga-Gómez, Rinaldo AU - Guerra-Chaviano, Pedro Pablo AU - Zúñiga-Rosales, Yaíma AU - Marcheco-Teruel, Beatriz AU - Rodríguez-Acosta, Mireida AU - Noa-Romero, Enrique AU - Enríquez-Puertas, Juliet AU - Porto-González, Delia AU - Leon-Monzon, Kalet AU - Chen, Guan-Wu AU - Martinez, Luis Herrera AU - Valdés-Balbín, Yury AU - García-Rivera, Dagmar AU - Vérez-Bencomo, Vicente AU - The Soberana 01B Clinical Trial team TI - A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial AID - 10.1101/2021.02.22.21252091 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.22.21252091 4099 - http://medrxiv.org/content/early/2021/03/03/2021.02.22.21252091.short 4100 - http://medrxiv.org/content/early/2021/03/03/2021.02.22.21252091.full AB - We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excellent safety profile one month after vaccination for all participants, similar to that previously found during vaccination of naïve individuals; b) a single dose of vaccine induces a >20 fold increase in antibody response one week after vaccination and remarkably 4-fold higher virus neutralization compared to the median obtained for Cuban convalescent serum panel. These preliminary results prompt initiation of a phase II trial in order to establish a general vaccination protocol for convalescents.Competing Interest StatementFinlay Vaccine Institute and Center for Molecular Immunology has filed patent applications relating to use vaccination in individuals with preexisting immunity SARS-CoV-2Clinical TrialIFV/COR/07 RPCE00000349Clinical Protocols https://rpcec.sld.cu/trials/RPCEC00000349 Funding StatementThis work was partially funded by Fondo de Ciencia e Innovacion (FONCI) from the Ministry of Science and Enviroment of Cuba (Project-2020-20)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Independent Ethical Committee for the Study of Human Subjects in the Institute of Hematology and ImmunologyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will b e available at https://rpcec.sld.cu/trials/RPCEC00000349 or under request to author